ATE284694T1 - Uracilderivate enthaltende krebsmetastasen inhibitoren - Google Patents
Uracilderivate enthaltende krebsmetastasen inhibitorenInfo
- Publication number
- ATE284694T1 ATE284694T1 AT97940448T AT97940448T ATE284694T1 AT E284694 T1 ATE284694 T1 AT E284694T1 AT 97940448 T AT97940448 T AT 97940448T AT 97940448 T AT97940448 T AT 97940448T AT E284694 T1 ATE284694 T1 AT E284694T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer metastases
- unsubstituted
- inhibitors containing
- substituted
- uracil derivatives
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 abstract 1
- 102000013537 Thymidine Phosphorylase Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- -1 amidinothio, guanidino Chemical group 0.000 abstract 1
- 239000002257 antimetastatic agent Substances 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25130396 | 1996-09-24 | ||
| PCT/JP1997/003355 WO1998013045A1 (en) | 1996-09-24 | 1997-09-22 | Cancerous metastasis inhibitors containing uracil derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE284694T1 true ATE284694T1 (de) | 2005-01-15 |
Family
ID=17220808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97940448T ATE284694T1 (de) | 1996-09-24 | 1997-09-22 | Uracilderivate enthaltende krebsmetastasen inhibitoren |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6255314B1 (de) |
| EP (1) | EP0884051B1 (de) |
| JP (1) | JP3088758B2 (de) |
| KR (1) | KR100284413B1 (de) |
| AT (1) | ATE284694T1 (de) |
| AU (1) | AU699728B2 (de) |
| CA (1) | CA2238331C (de) |
| DE (1) | DE69731940T2 (de) |
| DK (1) | DK0884051T3 (de) |
| ES (1) | ES2235249T3 (de) |
| PT (1) | PT884051E (de) |
| WO (1) | WO1998013045A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4049477B2 (ja) | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
| FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
| NZ523970A (en) * | 2003-02-04 | 2005-02-25 | Ind Res Ltd | Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases |
| US8415315B2 (en) | 2004-05-06 | 2013-04-09 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for inhibiting the proliferation of cancer cells |
| JP5576591B2 (ja) * | 2005-01-26 | 2014-08-20 | 大鵬薬品工業株式会社 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| ATE554770T1 (de) | 2006-04-13 | 2012-05-15 | Taiho Pharmaceutical Co Ltd | Therapeutisches mittel gegen entzündliche darmerkrankungen |
| JP4852605B2 (ja) | 2006-06-30 | 2012-01-11 | 大鵬薬品工業株式会社 | 放射線治療増強剤 |
| TWI435725B (zh) * | 2007-10-11 | 2014-05-01 | Taiho Pharmaceutical Co Ltd | The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis |
| TWI429439B (zh) | 2007-10-11 | 2014-03-11 | Taiho Pharmaceutical Co Ltd | And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient |
| JP2010202591A (ja) * | 2009-03-04 | 2010-09-16 | Hokkaido Univ | 増殖性疾患の内用放射線治療剤 |
| AU2014266278B2 (en) | 2013-05-17 | 2017-07-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic effect prediction method for colorectal cancer patient in whom expression of TK1 protein has increased |
| HK1203071A1 (en) | 2013-06-17 | 2015-10-16 | 大鹏药品工业株式会社 | Stabilized crystal of tipiracil hydrochloride, and crystallization method for same |
| CN105906573A (zh) * | 2015-12-23 | 2016-08-31 | 嘉实（湖南）医药科技有限公司 | 一种替吡嘧啶中间体的制备方法 |
| WO2018069532A1 (en) * | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| WO2020247679A1 (en) * | 2019-06-04 | 2020-12-10 | Vanderbilt University | Wdr5 inhibitors and modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3450399B2 (ja) | 1993-12-28 | 2003-09-22 | 大鵬薬品工業株式会社 | 血管新生阻害剤 |
| KR100424934B1 (ko) | 1995-03-29 | 2004-07-27 | 다이호야쿠힌고교 가부시키가이샤 | 우라실유도체및이를함유하는항종양효과증강제및항종양제 |
-
1997
- 1997-09-22 AU AU42225/97A patent/AU699728B2/en not_active Ceased
- 1997-09-22 CA CA002238331A patent/CA2238331C/en not_active Expired - Fee Related
- 1997-09-22 US US09/077,209 patent/US6255314B1/en not_active Expired - Lifetime
- 1997-09-22 EP EP97940448A patent/EP0884051B1/de not_active Expired - Lifetime
- 1997-09-22 AT AT97940448T patent/ATE284694T1/de active
- 1997-09-22 JP JP10503999A patent/JP3088758B2/ja not_active Expired - Fee Related
- 1997-09-22 DE DE69731940T patent/DE69731940T2/de not_active Expired - Lifetime
- 1997-09-22 KR KR1019980703452A patent/KR100284413B1/ko not_active Expired - Fee Related
- 1997-09-22 WO PCT/JP1997/003355 patent/WO1998013045A1/ja not_active Ceased
- 1997-09-22 ES ES97940448T patent/ES2235249T3/es not_active Expired - Lifetime
- 1997-09-22 PT PT97940448T patent/PT884051E/pt unknown
- 1997-09-22 DK DK97940448T patent/DK0884051T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0884051A1 (de) | 1998-12-16 |
| CA2238331A1 (en) | 1998-04-02 |
| AU4222597A (en) | 1998-04-17 |
| CA2238331C (en) | 2003-02-25 |
| EP0884051B1 (de) | 2004-12-15 |
| EP0884051A4 (de) | 2001-06-13 |
| ES2235249T3 (es) | 2005-07-01 |
| JP3088758B2 (ja) | 2000-09-18 |
| DK0884051T3 (da) | 2005-01-24 |
| KR19990067441A (ko) | 1999-08-16 |
| US6255314B1 (en) | 2001-07-03 |
| DE69731940D1 (de) | 2005-01-20 |
| AU699728B2 (en) | 1998-12-10 |
| DE69731940T2 (de) | 2005-05-25 |
| WO1998013045A1 (en) | 1998-04-02 |
| KR100284413B1 (ko) | 2001-03-02 |
| PT884051E (pt) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE284694T1 (de) | Uracilderivate enthaltende krebsmetastasen inhibitoren | |
| MX9203551A (es) | Derivados de fenil amidinas utiles como inhibidores de agregacion de plaquetas. | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| ATE345122T1 (de) | Stabile emulsionszubereitungen | |
| MXPA06001274A (es) | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. | |
| CY1107001T1 (el) | Αζωτουχα ετεροκυκλικα παραγωγα καρβοξαμιδιου ή αλας αυτων ως αντιϊκοι παραγοντες | |
| EP0976748A4 (de) | Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben | |
| MY133473A (en) | Haterocyclic glycyl beta-alanine derivatives. | |
| NO20004485L (no) | Sykloalkenderivater, deres fremstilling og anvendelse | |
| TR200403436T2 (tr) | Kristalin 1-metilkarbapenem türevleri. | |
| DK1043310T3 (da) | Biphenylamidinderivater | |
| WO2003049690A3 (en) | Hiv integrase inhibitors | |
| DE60014043D1 (de) | Flouride von 4-substituierten piperidin-derivaten | |
| ATE272617T1 (de) | Sulfonamid-derivate | |
| DE60330758D1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
| DK1209151T3 (da) | 4-substituerede piperidinderivativer | |
| ATE194621T1 (de) | Pyrazolothiazolopyrimidin-derivate | |
| FI940171A0 (fi) | Ketorolaakkijohdannaisia, joiden gastrointestinaalinen ärsytys ja ulserointi ovat huomattavasti vähentyneet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0884051 Country of ref document: EP |